UB Paderborn / Katalog / Suche / in CDI

1 – 15 von 15

Sortiert nach

Accountability and financial statement presentation of early Western Australian banks, 1837-1880

Accounting history, 2018-11, Vol.23 (4), p.555-574

2018

Volltextzugriff (PDF)

Origins resting behind banking financial accountability of paragraphs 78 to 82 of the First Schedule of the Companies Act 1862 (UK)

Business history, 2022-04, Vol.64 (3), p.558-582

2022

Volltextzugriff (PDF)

The rise of financial accountability in British joint stock banks: 1825 to 1845

Financial history review, 2020-08, Vol.27 (2), p.234-255

2020

Volltextzugriff (PDF)

Accountability and financial statement presentation of early Western Australian banks, 1837-1880

Accounting history, 2018-11, Vol.23 (4), p.555-574

2018

Volltextzugriff (PDF)

Explore ALK: Alectinib activity in patients with ALK+ metastatic non-small cell lung cancer—A national real world analysis (GFPC 03-2019)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9092-9092

2023

Volltextzugriff (PDF)

Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study)

Lung cancer (Amsterdam, Netherlands), 2024-07, Vol.193, p.107843, Article 107843

2024

Volltextzugriff (PDF)

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

Cancer Immunology, Immunotherapy, 2023-01, Vol.72 (1), p.91-99

2023

Volltextzugriff (PDF)

Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601)

Journal of thoracic oncology, 2011-03, Vol.6 (3), p.576-582

2011

Volltextzugriff (PDF)

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

Journal of cancer research and clinical oncology, 2023-11, Vol.149 (16), p.15095-15102

2023

Volltextzugriff (PDF)

First-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort—ESCKEYP trial (GFPC 05-2018)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9091-9091

2021

Volltextzugriff (PDF)

Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)

Targeted oncology, 2023-11, Vol.18 (6), p.905-914

2023

Volltextzugriff (PDF)

PD6-3-3: Medical and economical impact of bone metastases in lung cancer patients: a prospective French national, multicentric study (GFPC 06-01 study)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S432-S432

2007

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(15)

Publikationsform

Artikel
(15)

Sprache

Englisch
(14)

Erscheinungsjahr

n.n

Thema

Life Sciences
(6)
Life Sciences & Biomedicine
(6)
Oncology
(6)
Science & Technology
(6)
Non-Small Cell Lung Cancer
(5)
Cancer
(4)
Accountability
(3)
Accounting
(3)
Humans
(3)
Immunotherapy
(3)
Lung Cancer
(3)
Lung Neoplasms - Pathology
(3)
Medicine
(3)
Medicine & Public Health
(3)
Social Sciences
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Banking
(2)
Business & Economics
(2)
Cancer Research
(2)
Carcinoma, Non-Small-Cell Lung - Pathology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Accountability and financial statement presentation of early Western Australian banks, 1837-1880

Origins resting behind banking financial accountability of paragraphs 78 to 82 of the First Schedule of the Companies Act 1862 (UK)

The rise of financial accountability in British joint stock banks: 1825 to 1845

Accountability and financial statement presentation of early Western Australian banks, 1837-1880

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

Explore ALK: Alectinib activity in patients with ALK+ metastatic non-small cell lung cancer—A national real world analysis (GFPC 03-2019)

Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study)

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer

Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601)

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

First-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort—ESCKEYP trial (GFPC 05-2018)

Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS G12C -Mutant Lung Cancer

PD6-3-3: Medical and economical impact of bone metastases in lung cancer patients: a prospective French national, multicentric study (GFPC 06-01 study)

Suchergebnisse filtern